Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Cobimetinib as a Single Agent or in Combination with other Anticancer Agents in Patients with Advanced Solid Tumors

Trial Profile

Phase I Study of Cobimetinib as a Single Agent or in Combination with other Anticancer Agents in Patients with Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 10 Apr 2018 Status changed from recruiting to active, no longer recruiting.
    • 04 Oct 2017 Planned number of patients changed from 12 to 42.
    • 04 Oct 2017 Planned End Date changed from 1 Sep 2018 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top